Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Queen Mary University of London: Clinical Trials & FDA Approval Profile

Queen Mary University of London (Global / Institutional) sponsors 22 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 8 active protocols (4 recruiting now), 8 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)18.2%
Median Closed Enrollment vs National (145 pts)146 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Queen Mary University of London
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)22
Active Pipeline (Recruiting Now)8 (4)
Completed vs Stopped Early8 / 4 (18.2%)
Median Closed Actual Enrollment146 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Queen Mary University of London
Hospital Research SiteLocationShared Protocols
Barts Health NHS TrustLondon4

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Queen Mary University of London
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT04695080ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple SclerosisPhase II/IIIACTIVE NOT RECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Queen Mary University of London Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI